GCM
ANAB icon

Graham Capital Management’s AnaptysBio ANAB Stock Holding History

Graham Capital Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-15,320
Closed -$469K – 1213
2025
Q3 		$469K Buy
+15,320
New +$352K 0.01% 642
2025
Q1 		– Sell
-18,954
Closed -$251K – 1275
2024
Q4 		$251K Buy
+18,954
New +$459K ﹤0.01% 1002

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Graham Capital Management's ANAB Position: Q4 2025 in Review

Graham Capital Management sold out of AnaptysBio (ANAB) in Q4 2025, closing a stake of 15,320 shares — an estimated $469K sold.

Graham Capital Management first reported a position in ANAB in Q4 2024 and held it in 2 quarters. The position peaked at $469K in Q3 2025. 179 funds tracked by Wall St. Rank hold ANAB as of Q4 2025.

  • Graham Capital Management reported no remaining AnaptysBio position as of Q4 2025 after selling out during the quarter.
  • Graham Capital Management sold 15,320 AnaptysBio shares in Q4 2025, an estimated $469K.
  • Graham Capital Management first reported a position in AnaptysBio in Q4 2024 and held it in 2 quarters.
  • Graham Capital Management's AnaptysBio position peaked at $469K in Q3 2025.
  • 179 funds tracked by Wall St. Rank held AnaptysBio as of Q4 2025.

Based on Graham Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.